A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of cadonilimab combined with AK112 as second-line therapy in patients with advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
BIOLOGICAL: AK104+AK112
Progression-Free-Survival, Defined as the time between signing the informed consent form to the disease progression (according to RECIST v1.1 criteria) or death due to any cause., From the first drug administration up to two years
Objective Response Rate, Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1., From the first drug administration up to two years|Disease control Rate, Defined as the proportion of patients who achieved complete response (CR), partial response (PR), and stable disease (SD) according to RECIST v1.1., From the first drug administration up to two years|Overall survival, Defined as the time between the first dose to death due to any causes., From the first drug administration up to two years|Incidence of Adverse Events, Use NCI-CTCAE version 5.0 for classification and grading., From the first drug administration to within 90 days for the last dose
To evaluate the efficacy and safety of cadonilimab combined with AK112 as second-line therapy in patients with advanced hepatocellular carcinoma.